Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
Aims. To investigate the correlations between renal biomarkers and the treatment outcomes of ranibizumab for diabetic macular edema (DME). Methods. This hospital-based study retrospectively enrolled 88 eyes from 67 patients who had received one-year intravitreal ranibizumab treatment for DME. Best-c...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2020/7239570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560160156942336 |
|---|---|
| author | Ivan Pochou Lai Wei-Lun Huang Chung-May Yang Chang-Hao Yang Tzyy-Chang Ho Yi-Ting Hsieh |
| author_facet | Ivan Pochou Lai Wei-Lun Huang Chung-May Yang Chang-Hao Yang Tzyy-Chang Ho Yi-Ting Hsieh |
| author_sort | Ivan Pochou Lai |
| collection | DOAJ |
| description | Aims. To investigate the correlations between renal biomarkers and the treatment outcomes of ranibizumab for diabetic macular edema (DME). Methods. This hospital-based study retrospectively enrolled 88 eyes from 67 patients who had received one-year intravitreal ranibizumab treatment for DME. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) at baseline and during the follow-up period were recorded. BCVA and OCT characteristics at baseline and their changes after ranibizumab treatment were compared between different proteinuria and estimated glomerular filtration rate (eGFR) groups. Results. Of the 88 eyes studied, those with moderately increased proteinuria had a thicker central subfield foveal thickness (CFT) and a higher proportion of intraretinal cysts than those with no proteinuria (P=0.012 and 0.045, respectively) at baseline. After one year of ranibizumab treatment, the reduction in CFT was greater in patients with severely increased proteinuria than those with normal to mildly increased proteinuria (P=0.030). On the other hand, patients with an eGFR <30 tended to have poorer visual improvements than those with normal eGFR (P=0.044). Conclusions. After ranibizumab treatment for DME, patients with severe proteinuria tended to gain better anatomical improvement, while those with poor eGFR tended to have poorer visual improvement. |
| format | Article |
| id | doaj-art-164c1787ac674374b351ae5d6b1e98fd |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-164c1787ac674374b351ae5d6b1e98fd2025-02-03T01:28:10ZengWileyJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/72395707239570Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular EdemaIvan Pochou Lai0Wei-Lun Huang1Chung-May Yang2Chang-Hao Yang3Tzyy-Chang Ho4Yi-Ting Hsieh5National Taiwan University Hospital, Taipei, TaiwanDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, TaiwanDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, TaiwanAims. To investigate the correlations between renal biomarkers and the treatment outcomes of ranibizumab for diabetic macular edema (DME). Methods. This hospital-based study retrospectively enrolled 88 eyes from 67 patients who had received one-year intravitreal ranibizumab treatment for DME. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) at baseline and during the follow-up period were recorded. BCVA and OCT characteristics at baseline and their changes after ranibizumab treatment were compared between different proteinuria and estimated glomerular filtration rate (eGFR) groups. Results. Of the 88 eyes studied, those with moderately increased proteinuria had a thicker central subfield foveal thickness (CFT) and a higher proportion of intraretinal cysts than those with no proteinuria (P=0.012 and 0.045, respectively) at baseline. After one year of ranibizumab treatment, the reduction in CFT was greater in patients with severely increased proteinuria than those with normal to mildly increased proteinuria (P=0.030). On the other hand, patients with an eGFR <30 tended to have poorer visual improvements than those with normal eGFR (P=0.044). Conclusions. After ranibizumab treatment for DME, patients with severe proteinuria tended to gain better anatomical improvement, while those with poor eGFR tended to have poorer visual improvement.http://dx.doi.org/10.1155/2020/7239570 |
| spellingShingle | Ivan Pochou Lai Wei-Lun Huang Chung-May Yang Chang-Hao Yang Tzyy-Chang Ho Yi-Ting Hsieh Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema Journal of Diabetes Research |
| title | Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema |
| title_full | Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema |
| title_fullStr | Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema |
| title_full_unstemmed | Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema |
| title_short | Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema |
| title_sort | renal biomarkers for treatment effect of ranibizumab for diabetic macular edema |
| url | http://dx.doi.org/10.1155/2020/7239570 |
| work_keys_str_mv | AT ivanpochoulai renalbiomarkersfortreatmenteffectofranibizumabfordiabeticmacularedema AT weilunhuang renalbiomarkersfortreatmenteffectofranibizumabfordiabeticmacularedema AT chungmayyang renalbiomarkersfortreatmenteffectofranibizumabfordiabeticmacularedema AT changhaoyang renalbiomarkersfortreatmenteffectofranibizumabfordiabeticmacularedema AT tzyychangho renalbiomarkersfortreatmenteffectofranibizumabfordiabeticmacularedema AT yitinghsieh renalbiomarkersfortreatmenteffectofranibizumabfordiabeticmacularedema |